Form 4: Illumina Director Frances Arnold Receives Significant RSU Grant

Illumina, Inc. Director Frances Arnold was granted 3,780 shares of common stock in the form of restricted stock units, increasing her beneficial ownership to 20,907 shares.

Summary

• Frances Arnold, a Director of Illumina, Inc. (ILMN), received a grant of 3,780 shares of common stock.
• These shares are in the form of restricted stock units (RSUs).
• The transaction occurred on May 21, 2025.
• The RSUs were granted at a price of $0, indicating compensation rather than a purchase.
• Following this transaction, Ms. Arnold's total beneficial ownership of Illumina common stock is 20,907 shares.
• The RSUs will vest 100% on the earlier of the one-year anniversary of the grant date or the day preceding the annual meeting for the year following the grant, contingent on her continued service as a director.

Sentiment

Score: 7

Explanation: The grant of restricted stock units to a director is a positive signal, indicating continued alignment and commitment. It's a standard compensation practice, so not exceptionally positive, but certainly not negative.

Positives

• Grant of restricted stock units to a director indicates continued alignment of management/board interests with shareholders.
• The increase in beneficial ownership by a director can be seen as a vote of confidence in the company's future.

Risks

• The vesting of the restricted stock units is contingent on continued service as a director, meaning the shares could be forfeited if service ceases before vesting.

Future Outlook

The vesting schedule for the restricted stock units indicates a future milestone for the shares to become fully owned, contingent on the director's continued service.

Industry Context

This transaction is a routine compensation event for a director of a publicly traded company in the biotechnology/genomics industry. Granting restricted stock units is a common practice to align director incentives with long-term shareholder value.

Comparison to Industry Standards

• The grant of restricted stock units (RSUs) as part of director compensation is a standard practice across publicly traded companies, including those in the biotechnology and life sciences sectors like Illumina.
• While specific RSU amounts vary based on company size, director responsibilities, and compensation philosophy, this type of equity award is a common mechanism to align director interests with shareholder value.
• Comparable companies such as Thermo Fisher Scientific (TMO) or Danaher Corporation (DHR) also utilize equity-based compensation for their non-employee directors, often including RSUs, to incentivize long-term commitment and performance.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholders, as the value of the RSUs is tied to the company's stock performance.

Next Steps

• Vesting of the 3,780 restricted stock units on the earlier of the one-year anniversary of the grant date or the date immediately preceding the annual meeting of stockholders for the year following the grant.

Key Dates

Recommendation

Keywords

Illumina, ILMN, Form 4, Insider Transaction, Restricted Stock Units, RSU Grant, Director Compensation, Beneficial Ownership, Frances Arnold